Skip to main content

Advertisement

SpringerLink
Log in

The decreased achievement of therapeutic goal in lipid lowering therapy in obese and diabetic patients in Poland

  • Original article
  • Published:
Pharmacological Reports Aims and scope Submit manuscript

Abstract

Background

Statins are used to reduce a cardiovascular risk. However, the effectiveness of the therapy in many cases remains unsatisfactory. Therefore, the aim of this study was to evaluate the influence of obesity and diabetes on the achievement of therapeutic goal in lipid-lowering therapy in patients with a various cardiovascular risk in the daily clinical practice.

Methods

This study was conducted on the basis of questionnaires obtained from 7018 patients (41.4% obese, 65.9% viscerally obese and 25.3% diabetics) treated with statins for at least three months. The effectiveness of the treatment was assessed in a subgroup of 3218 patients with a full lipid profile.

Results

The LDL-cholesterol target, adjusted for cardiovascular risk, was obtained by 8.1% of patients, less frequently by those with a very high risk of a cardiovascular disease (3.7%), obesity (5.5%), visceral obesity (5.5%) and the type 2 diabetes (5.3%). The obese patients with type 2 diabetes were the least likely to reach the target (3.0%). Male gender, age, the body mass index (BMI) ≥ 28 kg/m2, visceral obesity, type 2 diabetes, and a low/moderate statin dose prescription were independent factors decreasing the chance of reaching the low-density lipoprotein (LDL) cholesterol target.

Conclusions

1. The prescribed statin doses do not fully explain the lower frequency of achieving the recommended target in a lipid-lowering therapy in the obese patients and the diabetics.

2. In the daily clinical practice the doses of statins are frequently insufficient and not adjusted for a cardiovascular risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jankowski P, Kloch-Badełek M, Dębicka-Dąbrowska D. Lipid-lowering drugs and control of hypercholesterolemia in Poland: recent evidence. Pol Arch Med Wewn 2011;121:164–71.

    PubMed  Google Scholar 

  2. Bandosz P, O’Flaherty M, Rutkowski M, Kypridemos C, Guzman-Castillo M, Gillespie D, et al. A victory for statins or a defeat for diet policies? Cholesterol falls in Poland in the past decade: a modeling study. Int J Cardiol 2015;185:313–9.

    Article  Google Scholar 

  3. Van Ganse E, Laforest L, Alemao E, Davies G, Gutkin S, Yin D. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;9:1389–99.

    Article  Google Scholar 

  4. März W, Wollschläger H, Klein G, Neiss A, Wehling M. Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial). Am J Cardiol 1999;84:7–13.

    Article  Google Scholar 

  5. Bożentowicz-Wikarek M, Kocełak P, Smertka M, Olszanecka-Glinianowicz M, Chudek J. Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis-guidelines vs reality. Pharmacol Rep 2012;64:377–85.

    Article  Google Scholar 

  6. Halava H, Korhonen MJ, Huupponen R, Setoguchi S, Pentti J, Kivimäki M, et al. Lifestyle factors as predictors of nonadherence to statin therapy among patients with and without cardiovascular comorbidities. CMAJ 2014;186: E449–56.

    Article  Google Scholar 

  7. Nag SS, Daniel GW, Bullano MF, Kamal-Bahl S, Sajjan SG, Hu H, et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm 2007;13:652–63.

    PubMed  Google Scholar 

  8. Cybulska B, Kłosiewicz-Latoszek L. Achieving target low-density lipoprotein cholesterol levels in the Polish population. Pol Arch Med Wewn 2012;122:9–11.

    PubMed  Google Scholar 

  9. World Health Organization. The challenge of obesity in the WHO European Region. Fact Sheet EURO 2005;13:1–4.

    Google Scholar 

  10. Alberti KG, Zimmet P, Shaw J. IDF epidemiology task force consensus group. The metabolic syndrome-a new worldwide definition. Lancet 2005;366:1059–62.

    Article  Google Scholar 

  11. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769–818.

    Article  Google Scholar 

  12. Zdrojewski T, Jankowski P, Bandosz P, Bartuś S, Chwojnicki K, Drygas W, et al. A new version of cardiovascular risk assessment system and risk charts calibrated for Polish population. Kardiol Pol 2015;10:958–61.

    Article  Google Scholar 

  13. Eliasson B, Svensson AM, Miftaraj M, Jonasson JM, Eeg-Olofsson K, Sundell KA, et al. Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus-an observational study from the Swedish National Diabetes Register. PLoS One 2011;4:e18744, doi:https://doi.org/10.1371/journal.pone.0018744.

    Article  Google Scholar 

  14. Krempf M, Simpson Jr RJ, Ramey DR, Brudi P, Giezek H, Tomassini JE, et al. Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Lipids Health Dis 2015;14:45, doi:https://doi.org/10.1186/s12944-015-0037-y.

    Article  Google Scholar 

  15. Goldman RE, Parker DR, Eaton CB, Borkan JM, Gramling R, Cover RT, et al. Patients’ perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med 2006;4:205–12.

    Article  Google Scholar 

  16. Bruckert E, Pouchain D, Auboiron S, Mulet C. Cross-analysis of dietary prescriptions and adherence in 356 hypercholesterolaemic patients. Arch Cardiovasc Dis 2012;105:557–65.

    Article  Google Scholar 

  17. Lang T, Arveiler D, Ferrières J, Amouyel P, Bingham A, Ducimetière P, et al. Declared knowledge, beliefs and practices for cardiovascular disease prevention in the French population. Rev Epidemiol Sante Publique 2001;49:239–48.

    CAS  PubMed  Google Scholar 

  18. Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002;19:596–604.

    Article  Google Scholar 

  19. Durack-Bown I, Giral P, d’Ivernois JF, Bazin C, Chadarevian R, Benkritly A, et al. Patients’ and physicians’ perceptions and experience of hypercholesterolaemia: a qualitative study. Br J Gen Pract 2003;53:851–7.

    PubMed  PubMed Central  Google Scholar 

  20. Olszanecka-Glinianowicz M, Chudek J. The level of health education in the Polish population. Ann Agric Environ Med 2013;20:559–65.

    PubMed  Google Scholar 

  21. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998;98:851–5.

    Article  CAS  Google Scholar 

  22. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Hazen SL, Ntanios F, et al. Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol 2006;97:1553–7.

    Article  CAS  Google Scholar 

  23. Gill JM, Brown JC, Bedford D, Wright DM, Cooney J, Hughes DA, et al. Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects. Atherosclerosis 2004;176:49–56.

    Article  CAS  Google Scholar 

  24. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz N, Blum CB, Robert H, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S1–45.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Metabolic Diseases, School of Health Science in Katowice, Medical University of Silesia, Katowice, Poland

    Michał Holecki, Gabriela Handzlik-Orlik & Jan Duława

  2. Department of Pharmacovigilance, Europharma Rachtan Co. Ltd., Katowice, Poland

    Agnieszka Almgren-Rachtan

  3. Pathophysiology Unit, Department of Pathophysiology, Medical Faculty in Katowice, Medical University of Silesia, Katowice, Poland

    Jerzy Chudek

Authors
  1. Michał Holecki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriela Handzlik-Orlik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Agnieszka Almgren-Rachtan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jan Duława
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jerzy Chudek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriela Handzlik-Orlik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holecki, M., Handzlik-Orlik, G., Almgren-Rachtan, A. et al. The decreased achievement of therapeutic goal in lipid lowering therapy in obese and diabetic patients in Poland. Pharmacol. Rep 69, 6–12 (2017). https://doi.org/10.1016/j.pharep.2016.09.009

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.pharep.2016.09.009

Keywords

Search

Navigation